Monthly shots of Amgen drug slash cholesterol up to 66 percent

CHICAGO (Reuters) - Monthly injections of an experimental drug from Amgen Inc slashed levels of cholesterol by up to an additional 66 percent in patients already taking statins, researchers said on Sunday, making it a potential strong rival to a similar drug being developed by Regeneron Pharmaceuticals Inc.

phonetic zoo homeschooling in oklahoma classical academy escondido